The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx ...
Patrizia Cavazzoni, leader of the Food and Drug Administration’s Center for Drug Evaluation and Research, is leaving the agency on Jan. 18, the latest top official to exit as Donald Trump ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...
FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...
acting director of the FDA’s Center for Drug Evaluation and Research, said in a news release. “This action and the agency’s designations to expedite the drug’s development and review ...
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
“It is the FDA’s role to ensure that drugs are safe and effective,” said Patrizia Cavazzoni, director of the FDA’s center for drug evaluation and research in a November statement.
“Today’s approval is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results